Syros Pharmaceuticals Acquires Tyme Technologies in $130M PIPE and Closes Merger
September 16, 2022
Syros Pharmaceuticals (NASDAQ: SYRS) closed its merger with Tyme Technologies, acquiring TYME’s pipeline assets and net cash at closing. The transaction included a concurrent oversubscribed $130 million private investment in public equity (PIPE), and the combined company trades on Nasdaq under the SYRS ticker.
- Buyers
- Syros Pharmaceuticals, Inc.
- Targets
- Tyme Technologies, Inc.
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Yarrow Bioscience Completes Merger with VYNE Therapeutics
July 27, 2026
Biotechnology
Yarrow Bioscience announced the completion of its merger with VYNE Therapeutics, with the combined company operating as Yarrow Bioscience, Inc. The transaction follows previously announced private financings totaling approximately $200 million and includes the initiation of dosing in a Phase 2a/2b trial of YB-101 for Graves' disease and thyroid eye disease.
-
N-Power Medicine Acquires Syapse
December 30, 2024
Healthcare Services
N-Power Medicine completed a stock-for-stock acquisition of Syapse on December 30, 2024, integrating Syapse’s precision-medicine technology, data assets and network of community oncologists into N-Power’s Kaleido Registry and AI-enabled point-of-care platform. Innovatus Capital Partners joined N-Power’s existing investors (including the Merck Global Health Innovation Fund) to provide ongoing funding; Canaccord Genuity served as Syapse’s exclusive financial advisor.
-
Novartis to Acquire MorphoSys in $2.9 Billion Deal
February 7, 2024
Pharmaceuticals
Novartis agreed to a voluntary public takeover offer to acquire MorphoSys AG for €68 per share, valuing the deal at about €2.7 billion (reported as $2.9 billion). The acquisition is intended to expand and complement Novartis’ oncology pipeline, including pelabresib (CPI-0610) and tulmimetostat (CPI-0209).
-
Bristol Myers Squibb Acquires RayzeBio in $4.1B Deal
December 26, 2023
Biotechnology
Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in an all-cash transaction, valuing the equity at approximately $4.1 billion. The deal is expected to close in the first half of 2024, subject to customary conditions, bringing RayzeBio’s actinium-based radiopharmaceutical platform and clinical pipeline into BMS’s oncology franchise.
-
Symeres Acquires Oncolines
January 10, 2023
Healthcare Services
Symeres, the Netherlands-headquartered transatlantic CRO & CDMO backed by Keensight Capital, has acquired Oncolines, an Oss-based oncology-focused CRO that provides early biology services and cell-line profiling assays. The add-on expands Symeres' oncology and precision-medicine biology capabilities and brings Oncolines' ~20 employees into the Symeres platform (part of NTRC Holding), increasing the group's integrated drug-discovery offering and proforma revenues to over €100m.
-
Ipsen Acquires Epizyme to Expand Oncology Portfolio
August 12, 2022
Pharmaceuticals
Ipsen completed its acquisition of Epizyme under a definitive merger agreement, acquiring all outstanding shares for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. The deal expands Ipsen’s oncology portfolio with Epizyme’s lead medicine Tazverik (tazemetostat) and development candidate EZM0414, among other preclinical programs.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.